Engineered cationic antimicrobial peptide (eCAP) prevents Pseudomonas aeruginosa biofilm growth on airway epithelial cells

Journal of Antimicrobial Chemotherapy

Volumn 71, Issue 8, 2016, Pages 2200-2207

  Lashua, Lauren P ^a   Melvin, Jeffrey A ^a   Deslouches, Berthony ^a,b   Pilewski, Joseph M ^a   Montelaro, Ronald C ^a,b   Bomberger, Jennifer M ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIMICROBIAL CATIONIC PEPTIDE; ANTIMICROBIAL CATIONIC PEPTIDE WBU2; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CEFTAZIDIME; CIPROFLOXACIN; COLISTIMETHATE; MEROPENEM; SODIUM CHLORIDE; TOBRAMYCIN; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; RECOMBINANT PROTEIN;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; BIOGENESIS; COCULTURE; CONTROLLED STUDY; CYSTIC FIBROSIS; CYTOTOXICITY; DRUG SYNTHESIS; ELECTRIC RESISTANCE; HUMAN; HUMAN CELL; LIQUID CULTURE; NONHUMAN; PH; PROTEIN ENGINEERING; PSEUDOMONAS AERUGINOSA; RESPIRATORY EPITHELIUM; RESPIRATORY TRACT MUCOSA; BIOFILM; CELL LINE; DRUG EFFECTS; EPITHELIUM CELL; GENETICS; GROWTH, DEVELOPMENT AND AGING; MICROBIOLOGY; PHYSIOLOGY;

ANTI-INFECTIVE AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; BIOFILMS; CELL LINE; COCULTURE TECHNIQUES; EPITHELIAL CELLS; HUMANS; PROTEIN ENGINEERING; PSEUDOMONAS AERUGINOSA; RECOMBINANT PROTEINS;

EID: 84982238874     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkw143     Document Type: Article

References (41)

1. Choo-Kang LR, Zeitlin PL. Type I, II, III, IV, and V cystic fibrosis transmembrane conductance regulator defects and opportunities for therapy. Curr Opin Pulm Med 2000; 6: 521-9.
2. Manzanares D, Krick S, Baumlin N et al. Airway surface dehydration by transforming growth factor b (TGF-b) in cystic fibrosis is due to decreased function of a voltage-dependent potassium channel and can be rescued by the drug pirfenidone. J Biol Chem 2015; 290: 25710-6.
3. Garland AL, Walton WG, Coakley RD et al. Molecular basis for pH-dependent mucosal dehydration in cystic fibrosis airways. Proc Natl Acad Sci USA 2013; 110: 15973-8.
4. Boucher RC. Airway surface dehydration in cystic fibrosis: pathogenesis and therapy. Annu Rev Med 2007; 58: 157-70.
5. Vidya P, Smith L, Beaudoin T et al. Chronic infection phenotypes of Pseudomonas aeruginosa are associated with failure of eradication in children with cystic fibrosis. Eur J Clin Microbiol Infect Dis 2016; 35: 67-74.
6. Emerson J, Rosenfeld M, McNamara S et al. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 2002; 34: 91-100.
7. Steckbeck JD, Deslouches B, Montelaro RC. Antimicrobial peptides: new drugs for bad bugs? Expert Opin Biol Ther 2014; 14: 11-4.
8. Lipsky BA, Holroyd KJ, Zasloff M. Topical versus systemic antimicrobial therapy for treating mildly infected diabetic foot ulcers: a randomized, controlled, double-blinded, multicenter trial of pexiganan cream. Clin Infect Dis 2008; 47: 1537-45.
9. Chen HC, Brown JH, Morell JL et al. Synthetic magainin analogues with improved antimicrobial activity. FEBS Lett 1988; 236: 462-6.
10. Flamm RK, Rhomberg PR, Simpson KM et al. In vitro spectrum of pexiganan activity when tested against pathogens from diabetic foot infections and with selected resistance mechanisms. Antimicrob Agents Chemother 2015; 59: 1751-4.
11. Lamb HM, Wiseman LR. Pexiganan acetate. Drugs 1998; 56: 1047-52; discussion 1053-4.
12. Hancock RE, Patrzykat A. Clinical development of cationic antimicrobial peptides: from natural to novel antibiotics. Curr Drug Targets Infect Disord 2002; 2: 79-83.
13. Matsuzaki K, Sugishita K, Miyajima K. Interactions of an antimicrobial peptide, magainin 2, with lipopolysaccharide-containing liposomes as a model for outer membranes of gram-negative bacteria. FEBS Lett 1999; 449: 221-4.
14. Zhao H, Mattila JP, Holopainen JM et al. Comparison of the membrane association of two antimicrobial peptides, magainin 2 and indolicidin. Biophys J 2001; 81: 2979-91.
15. Zhang L, Rozek A, Hancock RE. Interaction of cationic antimicrobial peptides with model membranes. J Biol Chem 2001; 276: 35714-22.
16. Hancock RE, Scott MG. The role of antimicrobial peptides in animal defenses. Proc Natl Acad Sci USA 2000; 97: 8856-61.
17. Braff MH, Gallo RL. Antimicrobial peptides: an essential component of the skin defensive barrier. Curr Top Microbiol Immunol 2006; 306: 91-110.
18. Deslouches B, Islam K, Craigo JK et al. Activity of the de novo engineered antimicrobial peptide WLBU2 against Pseudomonas aeruginosa in human serum and whole blood: implications for systemic applications. Antimicrob Agents Chemother 2005; 49: 3208-16.
19. Deslouches B, Phadke SM, Lazarevic V et al. De novo generation of cationic antimicrobial peptides: influence of length and tryptophan substitution on antimicrobial activity. Antimicrob Agents Chemother 2005; 49: 316-22.
20. Deslouches B, Gonzalez IA, DeAlmeida D et al. De novo-derived cationic antimicrobial peptide activity in a murine model of Pseudomonas aeruginosa bacteraemia. J Antimicrob Chemother 2007; 60: 669-72.
21. Deslouches B, Steckbeck JD, Craigo JK et al. Rational design of engineered cationic antimicrobial peptides consisting exclusively of arginine and tryptophan, and their activity against multidrug-resistant pathogens. Antimicrob Agents Chemother 2013; 57: 2511-21.
22. Deslouches B, Steckbeck JD, Craigo JK et al. Engineered cationic antimicrobial peptides to overcome multidrug resistance by ESKAPE pathogens. Antimicrob Agents Chemother 2015; 59: 1329-33.
23. Pezzulo AA, Tang XX, Hoegger MJ et al. Reduced airway surface pH impairs bacterial killing in the porcine cystic fibrosis lung. Nature 2012; 487: 109-13.
24. Phadke SM, Islam K, Deslouches B et al. Selective toxicity of engineered lentivirus lytic peptides in a CF airway cell model. Peptides 2003; 24: 1099-107.
25. Phadke SM, Deslouches B, Hileman SE et al. Antimicrobial peptides in mucosal secretions: the importance of local secretions in mitigating infection. J Nutr 2005; 135: 1289-93.
26. Hell E, Giske CG, Nelson A et al. Human cathelicidin peptide LL37 inhibits both attachment capability and biofilm formation of Staphylococcus epidermidis. Lett Appl Microbiol 2010; 50: 211-5.
27. Batoni G, Maisetta G, Brancatisano FL et al. Use of antimicrobial peptides against microbial biofilms: advantages and limits. Curr Med Chem 2011; 18: 256-79.
28. Moreau-Marquis S, Bomberger JM, Anderson GG et al. The DF508-CFTR mutation results in increased biofilm formation by Pseudomonas aeruginosa by increasing iron availability. Am J Physiol Lung Cell Mol Physiol 2008; 295: L25-37.
29. Smith EE, Buckley DG, Wu Z et al. Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients. Proc Natl Acad Sci USA 2006; 103: 8487-92.
30. Zemke AC, Shiva S, Burns JL et al. Nitrite modulates bacterial antibiotic susceptibility and biofilm formation in association with airway epithelial cells. Free Radic Biol Med 2014; 77: 307-16.
31. Rasgado-Flores H, Krishna Mandava V, Siman H et al. Effect of apical hyperosmotic sodium challenge and amiloride on sodium transport in human bronchial epithelial cells from cystic fibrosis donors. Am J Physiol Cell Physiol 2013; 305: C1114-22.
32. Myerburg MM, Latoche JD, McKenna EE et al. Hepatocyte growth factor and other fibroblast secretionsmodulate the phenotype of human bronchial epithelial cells. Am J Physiol Lung Cell Mol Physiol 2007; 292: L1352-60.
33. Zemke AC, Gladwin MT, Bomberger JM. Sodium nitrite blocks the activity of aminoglycosides against Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother 2015; 59: 3329-34.
34. Widdicombe JH. Altered NaCl concentration of airway surface liquid in cystic fibrosis. News Physiol Sci 1999; 14: 126-7.
35. Abou Alaiwa MH, Reznikov LR, Gansemer ND et al. pH modulates the activity and synergism of the airway surface liquid antimicrobials β-defensin-3 and LL-37. Proc Natl Acad Sci USA 2014; 111: 18703-8.
36. Gogoladze G, Grigolava M, Vishnepolsky B et al. DBAASP: database of antimicrobial activity and structure of peptides. FEMS Microbiol Lett 2014; 357: 63-8.
37. Travis SM, Singh PK, Welsh MJ. Antimicrobial peptides and proteins in the innate defense of the airway surface. Curr Opin Immunol 2001; 13: 89-95.
38. Batoni G, Maisetta G, Esin S. Antimicrobial peptides and their interaction with biofilms of medically relevant bacteria. Biochim Biophys Acta 2016; 1858: 1044-60.
39. Reffuveille F, de la Fuente-Nunez C, Mansour S et al. A broad-spectrum antibiofilm peptide enhances antibiotic action against bacterial biofilms. Antimicrob Agents Chemother 2014; 58: 5363-71.
40. Ribeiro SM, de la Fuente-Nunez C, Baquir B et al. Antibiofilm peptides increase the susceptibility of carbapenemase-producing Klebsiella pneumoniae clinical isolates to β-lactam antibiotics. Antimicrob Agents Chemother 2015; 59: 3906-12.
41. Paranjape SM, Lauer TW, Montelaro RC et al. Modulation of proinflammatory activity by the engineered cationic antimicrobial peptide WLBU-2. F1000Res 2013; 2: 36.